<div id="readability-page-1"><p><span>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report)</span> was downgraded by stock analysts at StockNews.com from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note issued on Monday.</p><p>Other research analysts have also recently issued reports about the company. Raymond James raised Prestige Consumer Healthcare to a &#34;moderate buy&#34; rating in a research report on Thursday, December 19th. DA Davidson increased their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, February 7th. Oppenheimer raised their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, February 13th. Canaccord Genuity Group raised their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a &#34;buy&#34; rating in a report on Friday, February 7th. Finally, Sidoti downgraded Prestige Consumer Healthcare from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. Three analysts have rated the stock with a hold rating and three have assigned  a buy rating to the company's stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $92.60.</p><p><b>Get Our Latest Stock Analysis on PBH</b></p><h2>Prestige Consumer Healthcare Price Performance</h2><p>PBH stock traded down $2.38 during trading on Monday, hitting $86.64. The company had a trading volume of 535,883 shares, compared to its average volume of 333,129. The company has a fifty day moving average price of $80.99 and a two-hundred day moving average price of $78.00. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The company has a market cap of $4.29 billion, a P/E ratio of 20.29, a P/E/G ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare has a fifty-two week low of $62.35 and a fifty-two week high of $90.04. </p><p>Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%.  Equities research analysts expect that  Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds have recently made changes to their positions in the business. Kestra Investment Management LLC bought a new stake in  Prestige Consumer Healthcare in the 4th quarter valued at about $27,000.  CIBC Private Wealth Group LLC boosted its stake in shares of  Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after buying an additional 152 shares during the last quarter.  Headlands Technologies LLC purchased a new position in  Prestige Consumer Healthcare in the fourth quarter valued at approximately $40,000.  Huntington National Bank lifted its stake in  Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after purchasing an additional 181 shares during the last quarter.  Finally, McIlrath &amp; Eck LLC raised its holdings in  Prestige Consumer Healthcare by 19.1% during the 4th quarter. McIlrath &amp; Eck LLC now owns 959 shares of the company's stock valued at $75,000 after acquiring an additional 154 shares during the period. 99.95% of the stock is owned by institutional investors. </p><h2>About Prestige Consumer Healthcare</h2> (Get Free Report)<p>Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.</p><h2>Read More</h2><ul><li>Five stocks we like better than Prestige Consumer Healthcare</li><li>How to Profit From Growth Investing </li><li>How to Protect Your Portfolio When Inflation Is Rising</li><li>Mastering Discipline: Overcoming Emotional Challenges In Trading</li><li>3 Tech Stocks Defying Sector Weakness and Thriving in 2025</li><li>Want to Profit on the Downtrend? Downtrends, Explained.</li><li>Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBCSA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?</h2><p>Before you consider Prestige Consumer Healthcare, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.</p><p>While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>StockNews.com has downgraded Prestige Consumer Healthcare (NYSE:PBH) from a "buy" to a "hold" rating. Other analysts have mixed views, with Raymond James upgrading it to "moderate buy" and DA Davidson raising the target price to $104. The stock traded down to $86.64, with a market cap of $4.29 billion and a P/E ratio of 20.29. Institutional investors own 99.95% of the stock. Prestige Consumer Healthcare develops and sells OTC health products in North America and internationally.</p>

StockNews.com Downgrades Prestige Consumer Healthcare (NYSE:PBH) to Hold